Our data collectively support the potential efficacy of JAK inhibitors and anti-TNF therapies in inflammatory macrophage responses in COVID-19 due to cellular phenotype associations with select inflammatory tissue diseases already proven to respond to these medications. The gene discussed is TNF; the disease is COVID-19.